DigitalDx Ventures

DigitalDx Ventures is a majority women-owned, early-stage venture capital fund founded in 2018 and headquartered in Menlo Park, California. Founded and led by Michele Colucci, the firm invests in health technology companies that use artificial intelligence and big data to transform diagnostics and therapeutics. Target areas include breast and other cancers, cardiovascular and kidney health, Alzheimer's disease, and mental health diagnostics. The fund has raised two funds with combined AUM under $25 million. With 8 investments to date, DigitalDx leads rounds at pre-seed through Series A stages with average checks of approximately $1.5 million. Portfolio companies include NOWDiagnostics (for which the firm led a $22.5 million Series B), Oxford Cancer Analytics, and GLX Analytix. Over 50% of portfolio companies feature women founders or C-suite executives. The investment team — including partners Eric Weiss, Vanessa Small, Melody Po, Sharad Mishra, and Erin Niehaus — applies a proprietary evaluation model called iTED (Investment Tool for Expert Diagnostics) that weighs team diversity, problem scale, and solution invasiveness. DigitalDx maintains a robust Experts and Entrepreneurs in Residence program with 24-plus distinguished operators from medicine, engineering, finance, law, and pharma, alongside a fellowship program that has enrolled more than 100 participants from top global universities. The firm's scientific advisory board includes Nobel Prize-winning scientists and Fortune 100 executives, giving portfolio companies access to clinical and commercial validation well beyond what the fund size alone would suggest.